Merck & Company Inc
MRK · NYSE120.16
120.16
USD-0.74-0.61%Data
Tickere
Titlu
Sursă
Merck begins tender offer to buy Terns Pharmaceuticals
SeekingAlpha
Terns Pharma shares surge on $6.7B Merck buyout deal at $53 per share
SeekingAlpha
Merck close to $6B acquisition of Terns Pharma to boost cancer portfolio: FT
SeekingAlpha
4 stocks to watch on Monday: MRK, DPZ, GILD, HON
SeekingAlpha
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more - CNBC
CNBC
📅IT’S A BIG WEEK OF EARNINGS! 📈 $GOOGL $AMZN $AMD $PLTR $QCOM $ARM $SMCI $RDDT $RBLX $SNAP $PYPL $AFRM $UBER $DIS $PEP $CMG $TSN $LLY $NVO $PFE $MRK $COP $SHEL $B WILL DELIVER RESULTS! 💰MAKE SMARTER INVESTMENT DECISIONS WITH ‘PRO PICKS AI’: 🎁GET 50% OFF ALL PRO PLANS FOR https://t.co/hCLP39WM0n
Week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM - Seeking Alpha
Seeking Alpha
Revolution Medicines plummets on report Merck walks from acquisition talks
SeekingAlpha
Merck is said to halt acquisition talks with cancer drug developer Revolution
SeekingAlpha
Key deals this week: Merck, Glencore, CrowdStrike, Marvell Technology, Steel Dynamics and more
Seeking Alpha
Merck in talks to acquire Revolution Medicines for about $30B - WSJ
SeekingAlpha
Revolution Medicines soars on report Merck in talks to buy
SeekingAlpha
Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation
MarketWatch
Merck completes cash tender offer for Cidara Therapeutics
SeekingAlpha
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
CNBC
Top global stories this week: Merck, SoftBank, Novo Nordisk among notable names
SeekingAlpha
Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more
Seeking Alpha
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
MarketWatch
4 stocks to watch on Friday: MRK, NU, GAP, BMY
SeekingAlpha
Merck seen nearing acquisition of Cidara Therapeutics in deal potentially above $3.3 billion
SeekingAlpha
Merck acquisition of Verona Pharma approved by court
SeekingAlpha
Merck will lay off employees and shed some real estate to cut $3 billion in costs
MarketWatch
Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more
Seeking Alpha
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
MarketWatch
Merck confirms $10B buyout of Verona Pharma
SeekingAlpha
Merck eyes $10B buyout of Verona Pharma - report
SeekingAlpha
RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants - CNBC
CNBC
Merck made $3B+ offer for MoonLake earlier this year - report
SeekingAlpha
Merck KGaA to buy Springworks for $3.9 billion
SeekingAlpha
SpringWorks jumps as Merck KGaA reportedly nears $3.5B buyout deal
SeekingAlpha
Merck absorbs $200 million in tariff costs into its earnings and full-year outlook
MarketWatch
SpringWorks Therapeutics jumps on report of Merck KGaA takeover talks
SeekingAlpha
🇺🇸EARNINGS THIS WEEK: • ALPHABET $GOOGL • AMAZON $AMZN • AMD $AMD • ARM HOLDINGS $ARM • QUALCOMM $QCOM • PALANTIR $PLTR • FORTINET $FTNT • SNAP $SNAP • ROBLOX $RBLX • WALT DISNEY $DIS • PAYPAL $PYPL • ELI LILLY $LLY • PFIZER $PFE • MERCK $MRK • NOVO NORDISK $NVO… https://t.co/n8VluKA3Gy https://t.co/NBsP246CAc
Incyte seesaws on report of potential Merck takeover interest
SeekingAlpha
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
MarketWatch
M&A deals roundup: Merck, Seadrill, Kraft Heinz, Spirit Airlines and more
SeekingAlpha
Merck buys Modifi for $30M plus up to $1.3B in potential payments
SeekingAlpha
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval - CNBC
CNBC
Merck says trial of combination treatment for colon cancer failed to meet main goal
MarketWatch
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
MarketWatch
Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
MarketWatch
Merck to buy experimental drug targeting B-cell diseases for up to $1.3 billion
MarketWatch
Merck discontinues late-stage trial of experimental lung cancer treatment after high number of adverse events
MarketWatch
Merck shares drop 10% as pharma giant scraps trial of promising cancer drug
MarketWatch
Întrebări frecvente
La ce aștepți?Începe să faci profit astăzi
Instrumente
Piețe
Mai mult
Resurse
Compară
Aplicație mobilă de profit
Descoperă lumea finanțelor în buzunarul tău
©
2026
Toate drepturile rezervate